Lixte Biotechnology Warrants
LIXTW
LIXTW was delisted on the 26th of November, 2025.
3 hedge funds and large institutions have $5K invested in Lixte Biotechnology Warrants in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
1.06% less ownership
Funds ownership: 1.72% → 0.66% (-1.1%)
40% less funds holding
Funds holding: 5 → 3 (-2)
83% less capital invested
Capital invested by funds: $29K → $5K (-$24K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$13 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
-$12K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.94K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $4K | +$13 | +100 | +0.1% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $1K | -$1.94K | -15,225 | -47% |
|
|
EAM
3
Empery Asset Management
New York
| – | -$12K | -99,835 | Closed |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| – | -$2K | -12,000 | Closed |
|
|
5
UBS Group
Zurich,
Switzerland
| – | +$11 | +90 | +1% |
|
LIXTW Hedge Fund Activity: Q3 2022 in Review
3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Lixte Biotechnology Warrants (LIXTW) for Q3 2022, worth a combined $5K — down 83% from $29K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of LIXTW and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Clear Street, adding an estimated $13. The largest seller was Empery Asset Management, exiting entirely with an estimated $12K sold.
- 3 institutional investors held Lixte Biotechnology Warrants (LIXTW) as of Q3 2022, down from 5 in Q2 2022.
- Funds reported $5K of Lixte Biotechnology Warrants stock for Q3 2022, down 83% quarter-over-quarter.
- 0 funds opened new Lixte Biotechnology Warrants positions in Q3 2022 and 2 closed out, a net change of -2 holders.
- The largest Lixte Biotechnology Warrants buyer in Q3 2022 was Clear Street, an estimated $13 added.
- The largest Lixte Biotechnology Warrants seller in Q3 2022 was Empery Asset Management, an estimated $12K sold.
Based on aggregated 13F filings for Q3 2022.